

- in systemic sclerosis, 2683  
toxic, 2688t, 2689  
weakness in, 156, 157, 2675, 2675t
- Peripheral node addressin (PNad), 372e-26
- Peripheral sensitization, 87
- Peripheral synovitis, 2169
- Peripheral T-cell lymphomas, 708
- Periplasmic space, 930
- Peristalsis, 255
- Peristaltic sounds, 106
- Perisylian network, 177
- Peritoneal carcinomatosis, 286, 287f, 288
- Peritoneal dialysis  
access for, 1824-1825  
complications of, 1825  
continuous ambulatory, 848, 1811, 1824  
continuous cyclic, 1824  
dose for, 1825  
for hypercalcemia, 2481  
principles of, 1824  
solutions for, 1824
- Peritoneal equilibrium test, 1825
- Peritoneal inflammation, 103
- Peritoneal lavage, as reawarming strategy, 478e-3
- Peritoneal papillary serous carcinoma, 120e-3-4
- Peritoneovenous shunt, 474
- Peritonitis, **846, 1989**  
abdominal pain in, 103, 106, 106t, 846  
acute, 1989  
ascites and, 287-288, 2065-2066  
aseptic, 1989  
bacterial, 288, 846-847, 1099, 2065-2066  
clinical features of, 288, 846-847, 1989  
diagnosis of, 288, 847  
etiology of, 846, 1028, 1989, 1989t  
hypovolemia in, 298  
pathophysiology of, 846, 846f  
in peritoneal dialysis, 848, 1825  
postoperative, 848  
prevention of, 847  
primary, 846-847, 1989  
prognosis of, 1989  
recurrence of, 847, 945t  
secondary, 847-848, 1989  
in transplant recipient, 924t, 927  
treatment of, 288, 847, 848, 1989  
tuberculous, 1111  
tumor markers in, 473t
- Peritonsillar abscess, 233, 235, 1097
- Periventricular white matter disease, 2568
- Perkinsus marinus*, 151e-4
- Perleche, 342f, 351
- Permeability transition pore, 444e-9
- Permethrin, 2744-2745, 2746
- Pernicious anemia  
APS-1 and, 2346t  
APS-2 and, 2346t, 2347t  
autoantibodies in, 372e-24t, 2347t  
cobalamin absorption in, 350e-1, 350e-1t, 644-645  
diagnosis of, 645  
juvenile, 645  
oral manifestations of, 237
- Pernio (chilblain), 478e-4, 1648f, **1649**
- Peroneal neuropathy, 463e-4, 463e-5f, 2683, 2692
- Peroxisomal catalase, 2058
- Peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ), 96e-6, 415e-2, 1959, 2415
- Perphenazine, 2721, 2722t
- PERRLA, 195
- Persistent light reaction, 389
- Persistent müllerian duct syndrome, 2355
- Persistent vegetative state, 1771
- Personality disorders, **2720**
- Personalized medicine, 425
- Pertactin, 1021, 1022
- Perthes test, 1651f
- Pertussis, **1021**  
clinical features of, 244, 1022-1023, 1023t  
complications of, 1023  
diagnosis of, 1023  
differential diagnosis of, 1023-1024  
epidemiology of, 1021-1022, 1021f, 1022f  
global considerations in, 1021, 1021f  
immune response in, 1022  
infection control measures, 1024  
pathogenesis of, 1022  
prevention of, 1024  
treatment of, 1024, 1024t
- Pertussis toxin, 1021, 1022
- Pertussis vaccine, 1022, 1024. *See also* Tetanus, diphtheria, acellular pertussis (Tdap) vaccine
- Pertuzumab  
action and targets of, 102e-5t, 102e-6, 103e-21, 103e-21t  
for breast cancer, 529  
Perverse effects, 18
- PET. *See* Positron emission tomography (PET)
- Petechiae. *See also* Purpura  
in anemia, 393  
etiology of, 999t  
in meningococemia, 781, 998  
pathogenesis of, 368  
in Rocky Mountain spotted fever, 1155, 1156f  
in vitamin C deficiency, 463t
- Petrous bone fractures, 457e-2
- Peutz-Jeghers syndrome  
lesions associated with, 538t  
oral manifestations of, 240t  
ovarian sex cord tumors in, 594  
pancreatic cancer risk in, 554  
polyp distribution in, 536, 538t  
skin manifestations of, 359, 360t
- Peyer's patches, 372e-26-27, 1049, 2696f
- PF-4 (platelet factor 4), 372e-13t, 727, 750
- PFA-100, 405, 407
- Pfeiffer syndrome (acrocephalopolysyndactyly), 435
- PGA (polyglandular autoimmune) insufficiency, 2366, 2483
- PGC-1 $\alpha$ , 444e-10
- P gene mutations, 357
- PGL-1 (phenolic glycolipid), 1122, 1126
- P-glycoprotein (PGP), 33, 34t, 37f, 102e-10, 284
- pH  
arterial, 315  
esophageal, 262  
urine, 1867
- Phaeohyphomycoses, 1355
- Phages, 86e-4
- Phagocyte(s). *See also* Neutrophil(s)  
microbial survival inside, 145e-7  
mononuclear. *See* Monocyte(s)  
pathogen encounters with, 145e-5, 145e-6f  
in primary immune deficiency diseases, 2104, 2105f  
in vitro tests of, 423
- Phagocyte activation defects, 419t, 421-422
- Phagocytosis, 145e-5, 1105-1106
- Phagophobia, 254
- Phagosome, 145e-7
- Phalen's sign, 2221
- Phantom pain, oral, 237
- Pharmaceutical companies, gifts from, 17e-3-4
- Pharmacodynamics  
of antibacterial drugs, 935, 935f  
definition of, 31  
principles of, 36
- Pharmacogenetics, 31, 425  
candidate gene studies in, 38, 38f  
in clinical practice, 41  
of platelet inhibitors, 277, 277t, 742-743, 743t
- Pharmacogenomics  
in clinical practice, 445, 451  
definition of, 32, 427  
genome-wide association studies in, 38-39, 39t  
vascular, 265e-4-5
- Pharmacokinetics, 31, **33**  
absorption of drugs, 33-34  
of antibacterial drugs, 934-935, 935f  
concepts, 34  
drug distribution, 34-35  
drug elimination, 35  
drug metabolites, 35  
high-risk, 35-36  
interactions in, 41-43, 42t
- Pharmacology, **31**  
clinical, 31  
diseases affecting drug concentration and response, 37  
genetic determinants of response to drugs, 38  
global considerations in, 32
- Pharyngitis, **231**  
arcanobacterial, 129t, 981  
*C. immitans*, 981  
*C. ulcerans*, 980  
diagnosis of, 232-233, 232f  
differential diagnosis of, 978  
in diphtheria, 978, 978f  
etiology of, 231, 965t, 1097  
*Fusobacterium*, 231  
in GERD, 262  
gonococcal, 1006, 1008, 1009t  
in HIV infection, 231  
in infectious mononucleosis, 1187, 1187t  
necrotizing, 1097  
plague, 1072-1073  
streptococcal  
clinical features of, 231-232, 965  
complications of, 233, 966  
diagnosis of, 232-233, 232f, 965, 1190t  
epidemiology of, 965  
etiology of, 231  
treatment of, 233, 965-966, 965t  
viral, 965t  
clinical features of, 231  
coxsackievirus, 1292  
etiology of, 231, 1202t  
treatment of, 233
- Pharyngoconjunctival fever, 231, 1208
- Phenacetin, 477t, 575, 577, 1856t, 1861
- Phenazopyridine, 473e-11t, 867
- Phencyclidine (PCP)  
actions of, 465e-5t, 469e-4  
adverse effects of, 469e-4, 2199  
overdosage/poisoning with, 469e-4, 473e-3, 473e-6
- Phendimetrazine, 2396
- Phenelzine  
adverse effects of, 2593, 2710t  
for depression, 2710t  
for migraine prevention, 2593  
for new daily persistent headache, 111  
overdosage/poisoning with, 473e-8t
- Phenformin, 34t, 644t
- Phenobarbital  
adverse effects of, 352, 2554t  
drug interactions of, 43, 246e-3t, 246e-5t, 246e-6t, 2554t  
for epilepsy, 2554t  
overdosage/poisoning with, 473e-10t, 2765t  
therapeutic monitoring of, 2765t
- Phenocopy, 40, 436
- Phenol exposure, 279
- Phenolic glycolipid (PGL-1), 1122, 1126
- Phenothiazines  
adverse effects of  
cardiac, 273e-4, 1467t  
cutaneous, 349, 353, 379, 389t  
heat-related illness, 479e-1  
hypothermia, 478e-1  
ocular, 206  
orthostatic hypotension, 146  
for dyspnea, 62
- Phenotoxicity, 91e-2t
- Phenotype, 435, 437
- Phenotypic heterogeneity, 435, 436t
- Phenotypic sex, 2349, 2352f
- Phenoxybenzamine  
for bladder dysfunction, 2672  
for frostbite, 478e-4t  
for hypertension, 1624t, 2330-2331
- Phentermine, 2396, 2453
- Phentermine/topiramate (PHEN/TPM), 2396, 2397t, 2453
- Phentolamine  
for adrenergic crisis, 1627  
for high-altitude pulmonary edema, 476e-3  
for hypertensive emergencies, 1627t  
for Irukandji syndrome, 2739